Patients with metastatic breast cancer initially presenting with overexpression of estrogen receptors (ERs) and absence of overexpression of HER2 research hub

Impact of 18F-fluoroestradiol (FES) Positron Emission Tomography (PET) on the therapeutic treatment of patients with ER+ and HER2- metastatic breast cancer in relapse after first-line therapy combining hormone therapy

This study looks at how a special scan called a FES-PET scan helps doctors make decisions about treating certain types of advanced breast cancer. It focuses on women whose cancer has returned after initial hormone therapy and aims to see if the scan changes their treatment plan.